FDA clears pTau217 blood test for Alzheimer's disease
-
By
-
Kathryn Wighton
-
August 24, 2026
-
2 min
Clinical Report: FDA clears pTau217 blood test for Alzheimer's disease
Overview
The FDA has cleared the Elecsys Phospho-Tau (217P) Plasma blood test to assist in identifying amyloid pathology in patients aged 55 and older with cognitive decline. This single-biomarker assay provides classifications to inform further diagnostic evaluation.
Background
Alzheimer's disease is a significant public health concern, with early and accurate diagnosis being crucial for patient management. The identification of amyloid pathology is a key component in the diagnostic process for Alzheimer's, and blood-based biomarkers offer a less invasive alternative to traditional imaging methods.
Data Highlights
The Elecsys pTau217 test classifies results as positive, intermediate, or negative for amyloid pathology. It was evaluated in patients aged 55 years and older with cognitive decline, showing high concordance with amyloid PET imaging.
Key Findings
- The Elecsys pTau217 test aids in both rule-in and rule-out assessments of amyloid pathology.
- It is intended for use alongside clinical information and other diagnostic findings.
- The test can be integrated into existing laboratory workflows without additional instrumentation.
- Results from the test are highly concordant with amyloid PET imaging.
- The assay has not been established for predicting future dementia or tracking therapeutic responses.
Clinical Implications
The Elecsys pTau217 test supports the diagnostic evaluation process but should be used in conjunction with other clinical assessments.
Conclusion
The clearance of the Elecsys pTau217 blood test by the FDA marks a significant step in the diagnostic evaluation of Alzheimer's disease.
Related Resources & Content
- Roche, FDA Press Release, 2026 -- FDA clears pTau217 blood test for Alzheimer's disease
- MDSpire News, 2026 -- P-Tau217/β-Amyloid Ratio Blood Test Gains Breakthrough Status
- MDSpire News, 2026 -- First Alzheimer's Test for Primary Care
- The Alzheimer's Association Clinical Practice Guideline, 2025 -- Blood-Based Biomarkers
- the pathologist — Blood Test Forecasts Alzheimer's Onset
- mdspire news — FDA approves tau PET imaging agent
- Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care
- Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings - Palmqvist - 2025 - Alzheimer's & Dementia - Wiley Online Library
- The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care - Dickerson - 2025 - Alzheimer's & Dementia - Wiley Online Library
- Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis - ScienceDirect
- Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease | Radiology | JAMA Neurology | JAMA Network
- The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET - Keshavan - 2026 - Alzheimer's & Dementia - Wiley Online Library
Based on findings from:
FDA clears pTau217 blood test for Alzheimer's disease
Kathryn Wighton. MDSpire News, 2026.
https://news.mdspire.com/neurology/articles/fda-clears-ptau217-blood-test-for-alzheimers-disease/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
